EBV‐positive diffuse large B‐cell lymphoma of the elderly: A case series from Peru

EBV‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly is an entity recently included in the WHO classification of lymphoid tumors. We have reviewed our experience and clinical outcomes of this distinct subtype of DLBCL. Between 2002 and 2009, cases of DLBCL were identified from medical r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2011-08, Vol.86 (8), p.663-667
Hauptverfasser: Beltran, Brady E., Castillo, Jorge J., Morales, Domingo, de Mendoza, Fernando Hurtado, Quinones, Pilar, Miranda, Roberto N., Gallo, Aly, Lopez‐Ilasaca, Marco, Butera, James N., Sotomayor, Eduardo M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:EBV‐positive diffuse large B‐cell lymphoma (DLBCL) of the elderly is an entity recently included in the WHO classification of lymphoid tumors. We have reviewed our experience and clinical outcomes of this distinct subtype of DLBCL. Between 2002 and 2009, cases of DLBCL were identified from medical records of the Hospital Nacional Edgardo Rebagliati Martins in Lima, Peru, and underwent pathological evaluation including immunohistochemistry for CD20, CD10, bcl‐6, MUM1/IRF4, and EBV‐encoded RNA in situ hybridization. Clinical data were gathered, tabulated, and reported descriptively. Survival analyses were performed using Kaplan‐Meier estimates. Out of 199 cases of DLBCL, 28 cases of EBV‐positive DLBCL of the elderly were identified. The median age was 75 years with male predominance (1.5:1). B‐symptoms were present in 43%, advanced stage in 50% and International Prognostic Index (IPI) score > 2 in 57% of patients; 68% of patients had a nongerminal center (NGC) phenotype. The complete response rates to R‐CHOP and CHOP were 63% and 33%, respectively. The median overall survival (OS) for the group was 5 months. In the univariate analysis, age ≥70 years, lymphocyte count
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.22078